Twist Bioscience Co. (NASDAQ:TWST) Director Sells $181,682.40 in Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 3,504 shares of the business’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $51.85, for a total transaction of $181,682.40. Following the sale, the director now directly owns 21,641 shares in the company, valued at $1,122,085.85. This trade represents a 13.94 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Robert Chess also recently made the following trade(s):

• On Monday, November 11th, Robert Chess sold 3,600 shares of Twist Bioscience stock. The shares were sold at an average price of $47.26, for a total transaction of $170,136.00.

Twist Bioscience Price Performance

TWST stock traded down $0.94 during midday trading on Monday, reaching $47.23. The company had a trading volume of 457,416 shares, compared to its average volume of 937,404. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The stock has a 50 day moving average price of $45.61 and a 200-day moving average price of $46.65. The company has a market capitalization of $2.80 billion, a price-to-earnings ratio of -13.12 and a beta of 1.82.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently bought and sold shares of the company. Thrivent Financial for Lutherans bought a new position in Twist Bioscience in the 3rd quarter valued at approximately $43,992,000. Point72 Asset Management L.P. lifted its holdings in shares of Twist Bioscience by 1,021.8% during the second quarter. Point72 Asset Management L.P. now owns 673,057 shares of the company’s stock worth $33,168,000 after purchasing an additional 613,057 shares during the period. Fred Alger Management LLC grew its stake in shares of Twist Bioscience by 720.7% in the second quarter. Fred Alger Management LLC now owns 654,877 shares of the company’s stock worth $32,272,000 after purchasing an additional 575,080 shares during the last quarter. State Street Corp increased its holdings in Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after purchasing an additional 526,028 shares during the period. Finally, Wellington Management Group LLP raised its position in Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares during the last quarter.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on TWST shares. Evercore ISI lifted their price objective on shares of Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Wolfe Research initiated coverage on Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Leerink Partners lifted their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Barclays dropped their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Finally, Scotiabank lifted their price objective on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $51.90.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.